abstract |
The present disclosure generally relates to the field of nicotine compositions for pulmonary administration, and uses thereof in treating viral infections, in particular coronaviruses. Specifically, the compositions contain a bronchodilator and are administered in the form of an aerosol generated by a nebulizer. |